logo
Millions of Eggs Recalled After Dozens Sickened With Salmonella

Millions of Eggs Recalled After Dozens Sickened With Salmonella

Mint5 hours ago

(Bloomberg) -- The US Food and Drug Administration said more than 20 million eggs have been recalled after 21 people were hospitalized with salmonella.
The eggs, distributed by the August Egg Company, were sold to retailers including Walmart Inc. and Safeway Stores Inc. between February 3 and May 19. The sell-by dates ranged from March 4 to June 19, the FDA said with its full list of brands involved.
August Egg Company recalled the eggs on June 6 and the US Centers for Disease Control and Prevention said it was opening an investigation into the outbreak.
Overall, 79 people across seven states got sick with a strain of salmonella linked to the eggs, according a statement from the CDC.
California has recorded 63 people sick with salmonella. Nevada and Washington have four people who are sick. Arizona, New Jersey, Nebraska and Kentucky have reported three people or less.
Symptoms of salmonella include diarrhea, fever and stomach cramps, the CDC says. The symptoms usually appear six hours to six days after swallowing the bacteria. Most people will recover four to seven days later without treatment, according to the Atlanta-based agency.
The US experienced an egg shortage earlier this year due to an ongoing bird flu outbreak in poultry, sending egg prices soaring to record highs. Prices have cooled in recent weeks as the outbreak slowed.
The recall also comes as the US is seeing another salmonella outbreak linked to whole cucumbers that has sickened 45 people and hospitalized 16, according to the CDC.
The CDC says the true number of people who are sick across the two outbreaks is likely higher than reported as it takes three to four weeks to determine if a sick person is part of an outbreak.
More stories like this are available on bloomberg.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Advent to invest $175 million in Felix Pharma to acquire minority stake
Advent to invest $175 million in Felix Pharma to acquire minority stake

The Hindu

time3 hours ago

  • The Hindu

Advent to invest $175 million in Felix Pharma to acquire minority stake

Advent, a private equity investor, has announced that funds managed by it have signed a definitive agreement to invest $175 million via primary and secondary capital for a significant minority stake in Dublin, Ireland-based Felix Pharmaceuticals Pvt. Ltd. (Felix), a global Gx animal pharma player. Felix Pharma is one of the developers and manufacturer of off-patent medicines for companion animals. Felix develops, manufactures and supplies to distributors and other branded Gx players for private labelling, particularly in the U.S. Shweta Jalan, Managing Partner, Advent, said, 'Healthcare has been a long-standing focus for us, and strong parallels we see between success in human Gx globally and emerging opportunity in animal health Gx. Felix is well positioned to lead this space with its strong leadership, broad portfolio, and robust R&D and commercial capabilities.' 'Its rapid growth and high customer satisfaction make it a differentiated platform, and we are excited to support Neeraj and the Felix team in scaling it into a global franchise,' she added, Founded in 2015 by Neeraj Agrawal, a McKinsey alum, Sir Jonathan Symonds, Chair of GSK and with 30 years of experience in global pharmaceuticals, and Dr. Shumeet Banerji, ex-CEO of Booz-Allen, Felix said it has pursued strategic growth through a disciplined approach, While the company achieved its first U.S. FDA approval in 2020, it has quickly scaled to a 14 commercialised product portfolio and has several others in advanced stages of pipeline. It has a USFDA-approved oral solid facility dedicated to animal health products and an injectable facility that is expected to be ready by Q3 2025. Neeraj Agrawal, Co-Founder, Felix Pharma, said, 'As we scale in a fast-evolving market, we were looking for a partner who brings not just capital, but also deep operating expertise and the right mindset and networks to help us grow faster and stronger. Advent's strong track record in healthcare and pharma, and their close involvement in building strong businesses, gives us great confidence.'

Ahmedabad reports highest single-day rise in Covid cases; state's active case tally at 1,109
Ahmedabad reports highest single-day rise in Covid cases; state's active case tally at 1,109

Indian Express

time3 hours ago

  • Indian Express

Ahmedabad reports highest single-day rise in Covid cases; state's active case tally at 1,109

With 131 new cases of Covid in Ahmedabad — the highest single-day rise in the city — the state recorded 235 new cases on Monday. Ahmedabad Municipal Corporation's (AMC's) health officials confirmed that Monday's was the highest number of Covid cases that the city has reported in 24 hours after the fresh spate of cases. The total number of active cases in the state stands at 1,109, including 33 people who needed hospitalisation. Others are undergoing OPD-based treatment. Another 106 people, who recovered from the virus, were discharged on Monday. As per a health bulletin released by the state government, no death was reported in Gujarat on Monday. In Ahmedabad, the tally of cases has gone up to 916, including 646 active. Ahmedabad city has reported two deaths due to Covid. Among the active cases in Ahmedabad, highest were reported in the the west zone at 211, followed by the north west zone at 204, and south west zone at 114. The remaining zones have reported 50 (south zone), 25 (north zone), 24 (east zone), 18 (central zone) cases. According to the Indian SARS-CoV-2 Genomics Consortium (INSACOG), the XFG variant of the Covid-19 has been recently found in a total of 163 samples — with the highest (89) in Maharashtra, followed by Tamil Nadu (16), Kerala (15), Gujarat (11), and Andhra Pradesh, Madhya Pradesh and West Bengal (6 each). The recombinant XFG variant harbours four key spike mutations and has achieved rapid global spread following its initial detection in Canada, according to an article in The Lancet journal. In May, as many as 159 samples were detected with XFG variant, two in April, and two in June yet, data shows. India's active Covid case tally crossed the 6,000 mark, with 769 having been added to it in 48 hours, according to Union Health Ministry data released on Sunday

Luxury skincare expansion: L'Oreal acquires majority stake in Medik8; announces 1 billion Euro deal
Luxury skincare expansion: L'Oreal acquires majority stake in Medik8; announces 1 billion Euro deal

Time of India

time4 hours ago

  • Time of India

Luxury skincare expansion: L'Oreal acquires majority stake in Medik8; announces 1 billion Euro deal

Cosmetics maker L'Oreal agreed to acquire a majority stake in British skincare brand Medik8, in a strategic move to strengthen its presence in the booming skincare market. The French beauty giant announced the deal on Monday, though financial terms were not disclosed. The transaction, which sees UK-based private equity firm Inflexion selling its majority holding, reportedly values Medik8 at around 1 billion Euro, according to a source familiar with the matter. Inflexion will retain a minority share, while L'Oreal has secured the option to eventually buy out all remaining shareholders, Reuters reported. 'We are delighted to welcome Medik8 to the L'Oréal family. As a premium skincare range, with high levels of proven efficacy at an accessible price point, Medik8 perfectly complements our existing skincare portfolio,' Cyril Chaupuy, president of L'oreal Luxe said. 'This acquisition further strengthens L'Oreal's luxe portfolio, adding a premium science-backed skincare brand with a proven track record of success, with strong potential for global growth,' the company said in a statement. L'Oreal will begin consolidating Medik8's sales once the transaction officially closes. The acquisition is expected to be finalised in the coming months, pending regulatory approvals and standard closing conditions. Simon Coble, CEO of Medik8 also expressed excitement on the brand's behalf. 'I am delighted to be joining forces with a company which shares our vision for the brand's future growth and whose core values align with our deep commitment to science, innovation and above all, results without compromise. I look forward to the next stage in Medik8's journey, as we work together to bring our innovative products to a wider audience.' Founded in the UK, Medik8 has built a loyal customer base with its vitamin A-focused anti-ageing creams and serums. The brand is seen as a natural fit for L'Oreal's luxury division, which includes skincare and fragrance names such as Lancome, Aesop, and Miu Miu. Last year, sales in L'Oreal's luxe segment grew by just 2.7%, its weakest performance across divisions, as inflation pushed consumers toward more affordable alternatives. However, the unit scrored better than rival LVMH's beauty arm. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store